se of Paarthadi Kwath along with Hridbasti compared with Calcium channel blocker in Essential Hypertension.

Phase 3

• Conditions: Health Condition 1: I10- Essential (primary) hypertension

• Registration Number: CTRI/2023/06/054158
• Lead Sponsor: DPU Seed Money with letter no DP

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 June 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. 18-70 years of either gender.

2. Systolic Blood pressure less than 170mmHg more than or equal to 140mmHg.

3. Distolic Blood Pressure less thann or equal to 110mmHg and more than 90mmHg.

4. Hypertension Stage II according to JNC seventh report 2004.

Exclusion Criteria

1. Patient that past history of atrial fibrillation, acute coronary syndrome ,myocardial infarction, stroke, right ventricular hypertrophy, left ventricular hypertrophy, severe arrhythmia in last 6 months.

2. Symptomatic patient with clinical feature of early heart failure.

3. Secondary hypertension.

4. Patient with concurrent serious hepatic dysfunction, renal dysfunction, uncontrolled pulmonary dysfunction.

5. Patient suffering with diabetes nephropathy.

6. Women who are pregnant, lactating or on estrogen replacement therapy.

7. Alcohol and Drug abusers.

8. Accelerated and maligant hypertension.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Patient showing relief from clinical sign and symptoms of essential hypertension.Timepoint: 0, 4 and 7 day

Secondary Outcome Measures

Name	Time	Method
To complete seven days treatmentTimepoint: 0, 4 and 7 day